for women
for men
What is Juvéderm® VOLUX? Juvéderm® VOLUX is a structural hyaluronic acid gel indicated for: –– Restoration of facial volume1 in the chin and jawline*2,3 –– Refinement and creation of facial volume1 in the chin and jawline*2,3 Juvéderm® VOLUX demonstrates the highest elasticity† and cohesivity† within the VYCROSS® collection4–6 These attributes allow Juvéderm® VOLUX to be sculpted,6 offering improved chin projection and enhanced lift capacity compared with Juvéderm® VOLUMA in vitro.2,6 For patients who want to restore or create structure in the chin and jawline, Juvéderm® VOLUX offers long lasting results that may be seen at 18–24 months‡6,7 *There is no available clinical trial data on the efficacy and tolerance of Juvéderm® VOLUX injected into anatomical regions other than the chin and jawline1 Rheological properties of gels are characteristics to describe their physical responses to applied forces in vitro and should not be individually translated to clinical performance4,5
Patients were given two treatments (initial and top-up) approximately 30 days apart, based on the investigator’s clinical experience. Top-up treatment was given to 69/90 patients.2 Based on comparative preclinical in vitro testing, and results from repeat treatment data, added to Juvéderm® VOLUX clinical study showing duration beyond 18 months after initial treatment or initial + top-up treatment in the chin and jaw, as well as clinical results for predicate device Juvéderm® VOLUMA with lidocaine showing 24-month duration in the midface, established Juvéderm® VOLUX as having an in situ duration of 18–24 months6,7
‡
References
1. Allergan Inc. Juvéderm® VOLUX Directions for Use. 72778JR11. Revision 2019-06-03 2. Allergan Inc. Data on File. Juvéderm® VOLUX final clinical study report & clinical evaluation report – efficacy and duration data. INT/0654/2018. October 2018 3. Ogilvie P, et al. Poster presentation at Aesthetic & Anti-Aging Medicine World Congress 2018 4. Allergan Inc. Unpublished Data. Juvéderm® (Gel Elasticity G’) data. INT/0141/2019. March 2019 5. Allergan Inc. Unpublished Data. Juvéderm® gel cohesivity data. INT/0011/2018a(1). May 2018 6. Allergan Inc. Juvéderm® VOLUX DOF. Clinical Evaluation Report. INT/0663/2018. October 2018 7. Allergan Inc. Data on File. INT/0074/2019. Juvéderm®VOLUX final clinical evaluation report, July 2018. January 2019 Models treated with Juvéderm® VOLUMA with lidocaine and Juvéderm® VOLUX. Results may vary between patients. Images provided by Allergan for illustrative purposes only Allergan Norden AB, Strandbergsgatan 61, 112 51 Stockholm, Sverige To report Adverse Events please contact: ProductSurveillance_EAME@Allergan.com
www.juvederm.se www.juvederm.no www.juvederm.dk www.juvederm.fi
juvedermSE juvedermNO juvedermDK juvedermFI
juvederm.se juvederm.no juvederm.dk juvederm.fi
ND-JUV-1950026. Date of preparation: August 2019
†